跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
fibronectin matrix
首页
药物
fibronectin matrix
fibronectin matrix
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF
申请人: UNIV TARTU
优先权: 2019
CN
EP
US
WO
6 件公开
Compositions and methods for treatment of angiogenesis in pathological lesions
申请人: ZARDI LUCIANO
优先权: 2001
US
5 件公开
ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX
申请人: GENEMEDICINE CO LTD
优先权: 2016
CN
EP
US
3 件公开
IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO EXTRACELLULAR MATRIX
申请人: UNIV MONASH
优先权: 2020
EP
US
WO
3 件公开
BIOLOGICALLY ACTIVE COLLAGEN HYBRIDIZING PEPTIDES
申请人: 3HELIX INC
优先权: 2021
CN
EP
WO
3 件公开
METHODS FOR CELL EXPANSION, DIFFERENTIATION, AND/OR HARVESTING OF NATURAL KILLER CELLS USING HOLLOW-FIBER MEMBRANES
申请人: TERUMO BCT INC
优先权: 2022
CN
EP
WO
3 件公开
VASCULAR PLANT BASED SCAFFOLD AND IN-VITRO METHOD FOR NEURAL STEM CELL CULTURE
申请人: UNIV OTTAWA
优先权: 2023
CN
EP
WO
3 件公开
ADENO ASSOCIATED VIRUS (AAV) MEDIATED LYSYL OXIDASE GENE THERAPY FOR KERATOCONUS AND THE CONSTRUCTS THEREOF
申请人: NARAYANA NETHRALAYA FOUND
优先权: 2023
CN
EP
WO
3 件公开
IL-12 IMMUNOCONJUGATE
申请人: PHILOGEN SPA
优先权: 2011
EP
US
3 件公开
Silencing of tgf-beta receptor type II expression by sirna
申请人: KUMAR NALIN M
优先权: 2003
US
3 件公开
第 1 / 9 页
上一页
下一页
药物
反馈